Support nanotechnology research for early detection of Alzheimer’s and glioblastoma

Researching new ways of detecting brain disease earlier.

Alzheimer’s disease, Parkinson’s and glioblastoma are three of the most devastating and challenging neurological disorders.

Early detection of brain diseases is a major unmet need, as current diagnostic methods, such as PET and MRI scans, are often ineffective until the diseases are well advanced.

Why funding is needed

To advance our researchers’ work, we are seeking support of £50,000 to hire a bioinformatician for 12 months.

Their expertise will be essential in analysing the large volumes of data we are generating, helping us to identify and prioritise the most promising biomarkers, which can then be developed into clinically viable, non-invasive blood tests.

How researchers are working to enable earlier intervention

The Nanomedicine Lab develops advanced nanotechnology tools to discover minimally invasive blood biomarkers for the early detection of Alzheimer’s disease, Parkinson’s and glioblastoma.

By identifying specific blood-based biomarkers that can signal disease presence at very early stages, we aim to enable earlier intervention, significantly improving patient outcomes.

This approach will also allow for more precise monitoring of disease progression and treatment responses, providing both patients and clinicians with critical information to tailor therapeutic strategies.

Contact us

If you have any questions, please email us at GJBRC@manchester.ac.uk.